Arcutis Biotherapeutics Q3 2026 Results: Net Income $8.8M, Up 18.8% YoY
Arcutis Biotherapeutics reported a significant turnaround for the nine months ended September 30, 2026, achieving a net income of $12.5 million compared to a net loss of $33.5 million in the prior year period. This growth was driven by a 55% increase in net product revenue to $379.2 million, though operating expenses also rose to $362.4 million due to higher selling, general, and administrative costs.
- Key figure
- Net income $8.8M · +18.8% YoY